Weekly Summary Alert for Eli Lilly and Company

Eli Lilly and Company Eli Lilly and Company added the following items during the week of October 28, 2024 PRODUCT NEWS Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium FINANCIAL NEWS Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products ALL SEC FILINGS 8-K 10-Q 4 QUARTERLY AND ANNUAL REPORTS 10-Q INSIDER TRANSACTIONS 4 LLYMondayTuesdayWednesdayThursdayFridayOpening Price$894.87$898.21$798.50$836.51$828.00Last Trade$895.59$903.58$846.83$829.74$818.93Price Change+$2.89+$7.99-$56.75-$17.09-$10.81Percent Change+0.32%+0.89%-6.28%-2.02%-1.30%Day High$898.21$907.98$860.50$853.50$833.00Day Low$890.78$898.21$769.00$825.24$816.73Volume2,083,6133,170,32218,254,0146,578,8254,835,117 Visit the website →